Abstract:e23131 Background: Cancer Differentiation Analysis liquid biopsy (CDA) has been investigated as a viable clinical utility in NSCLC diagnosis, as well as a new candidate for part of an overall post-CT scan clinical diagnostic and treatment decision tool kit. It has been also evaluated in NSCLC diagnosis, combined with imaging technologies. Methods: This was a retrospective investigation in which 160 individuals were recruited at Changhai Hospital of Shanghai from July to Dec. in 2014. CDA and CT scan tests were performed on all samples before final confirmation by biopsy. For CDA tests, peripheral blood was drawn in EDTA tubes before operation. A performance predication model of CDA and CT scan test results was built using pROC package in R Language for the data of Area Under the Curve (AUC) and CDA threshold values. Further analysis was carried out based on the CDA threshold values. Results: Out of the 160 individuals, 40 were diagnosed as benign lung diseases selected as control group, 120 were confirmed as NSCLC by pathology. CDA and CT test data along with epidemiological information were collected and complied. Details of other statistical results were given in the Table below. Conclusions: CDA liquid biopsy is a novel, multi-level, multi-parameter based disease diagnosis technology with improvements in multiple areas including but not limited to higher sensitivity and specificity, ability to diagnose cancer early, no side effects, and covering a wide range of cancer sites. Results showed that AUC values of CDA were higher than those of CT scan for all NSCLC stage groups. CDA plus CT scan combination has the highest average AUC value for all stages. CDA test can provide more accurate and reliable diagnostic information and data for oncologists in making crucial clinical decisions. It is expected that CDA liquid biopsy technology will play an important and critical role in NSCLC diagnosis. [Table: see text]

A Novel Cancer Diagnostic Method: Fcla Assisted Sono-Dynamic Diagnosis

A Novel Cancer Imaging Method Using Chemiluminescence-Mediated Sonosensitization

Sonodynamic Diagnosis of Cancer with Sonosensitization of ATX-70 Mediated by Chemiluminescence Probe

Combined Classifier for Discriminating Cancerous Tissue from Normal Tissue Using Light-Induced Autofluorescence

Accurate Fluorescence Diagnosis of Cancer Based on Sequential Detection of Hydrogen Sulfide and pH

Tumor Detection with Sonodynamic Chemiluminescence from Atx-70 and Fcla under Ultrasonic Excitation

FCLA-assisted Photodynamic Diagnosis

Experimental Study on Photodynamic Diagnosis of Cancer Mediated by Chemiluminescence Probe

<title>High-sensitivity imaging method of singlet oxygen and superoxide anion in photodynamic and sonodynamic actions</title>

High-sensitive imaging method of singlet oxygen and Superoxide anion in photodynamic and sonodynamic actions

Characterization Of Small Focal Liver Lesions Using Real-Time Contrast-Enhanced Sonography - Diagnostic Performance Analysis In 200 Patients

Sonoluminescence Imaging and Its Biomedical Applications

A Novel CDA Liquid Biopsy Technology for Effective Non-Small Cell Lung Cancer Diagnosis.

Confocal reflectance/auto-fluorescence tomograpy (CRAFT) for early skin cancer diagnosis

FCLA Chemiluminescence from Sonodynamic Action in Vitro and in Vivo

Accurate Diagnosis of Early-Stage Lung Cancer by Targeting Lipid Droplets with a Two-Photon Near-Infrared Fluorescence Probe

Fcla-Enhanced Sonoluminescence Imaging In Vivo

Development of an Endoscopic Auto-Fluorescent Sensing Device to Aid in the Detection of Breast Cancer and Inform Photodynamic Therapy

CRAFT: Multimodality confocal skin imaging for early cancer diagnosis.

Multimodal microscopic imaging with deep learning for highly effective diagnosis of breast cancer

Localization of tumor by chemiluminescence probe during photosensitization action.